Skip to content

Effect of cell therapy in premature ovarian failure

Intraovarian Allotransplantation of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in Patients with Premature Ovarian Insufficiency (POI) : clinical trial Phase II/I

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210612051545N7
Enrollment
35
Registered
2023-07-19
Start date
2023-08-26
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary ovarian failure. Primary ovarian failure

Interventions

Intervention group: Two intratubal injections of allogeneic umbilical cord-derived mesenchymal stromal cells are performed in 15 patients with Primary Ovarian Insufficiency (POI). The injection of 5×1

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Have established regular menstrual cycle, oligomenorrhea / amenorrhea = 4 months FSH (Follicle-Stimulating Hormone) > 25 IU/mL ????????? ????? XX46 The duration of amenorrhea is less than 3 years The average diameter of the ovary is above 10 mm

Exclusion criteria

Exclusion criteria: Primary amenorrhea Thyroid dysfunction, TSH > 0.4 L/mIU Serious systemic diseases, cardiovascular, liver, kidney, blood system and all uncontrolled chronic diseases (diabetes, …) Pregnancy contraindications History of PID, endometriosis, ovarian cyst surgery, uterine myoma History of cancer, chemotherapy, radiation therapy Congenital abnormalities of the reproductive system Autoimmune diseases such as MS, SLE Spouse with sperm count less than 10 ml/m, and normal sperm shape less than 4% Smoking Positive viral tests for HCV, HBS, HIV,

Design outcomes

Primary

MeasureTime frame
Absence of side effects, including short-term and long-term, systemic or local side effects and severe or mild side effects. Timepoint: first 24 hours, 1st and 2nd week, 1st, 2nd, 3rd, 4th, 5th, 6th month after injection. Method of measurement: clinical examinations and laboratory tests.

Secondary

MeasureTime frame
Correction of hormonal status such as reduction of FSH level. Timepoint: First 24 hours, week 1 and 2, month 1, 2, 3, 4, 5, 6 after injection. Method of measurement: laboratory tests.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Bajouri

Tehran University of Medical Sciences

bajouri.md@gmail.com+98 21 2221 2537

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026